Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005842 · ClinicalTrials.gov registry record · Phase 1
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00005842: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005842 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005842, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with R115777 may kill more tumor cells.
Interventions
- BIOLOGICAL trastuzumab
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2000-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005842
The ClinicalTrials.gov registry entry for NCT00005842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which trastuzumab is the first listed.
NCT00005842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005842 about?
NCT00005842 is a clinical study titled "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer". Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used...
What is the current status of trial NCT00005842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2000-06.
What interventions are being tested in trial NCT00005842?
The interventions under investigation include: trastuzumab (BIOLOGICAL), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005842?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.